How Analysts Feel About BioCryst Pharmaceuticals, Inc. (BCRX) After Forming Bullish Descending Triangle Pattern?

December 8, 2017 - By Marguerite Chambers

Investors sentiment increased to 1.68 in 2017 Q2. Its up 0.18, from 1.5 in 2017Q1. It improved, as 15 investors sold BioCryst Pharmaceuticals, Inc. shares while 19 reduced holdings. 18 funds opened positions while 39 raised stakes. 66.24 million shares or 8.58% more from 61.01 million shares in 2017Q1 were reported.
Emory University holds 1.41% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 287,550 shares. Financial Architects holds 0% or 30 shares. Deerfield Mngmt Company accumulated 1.04% or 3.50 million shares. Northern Tru Corp has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Geode Mgmt Llc reported 654,584 shares. Franklin Street Advsr Nc invested in 0.05% or 49,000 shares. Aqr Capital Management Llc, a Connecticut-based fund reported 54,322 shares. 106,318 are owned by Credit Suisse Ag. Vanguard Grp, a Pennsylvania-based fund reported 6.01M shares. Eventide Asset Llc holds 0.1% or 290,000 shares. Royal Commercial Bank Of Canada reported 461 shares or 0% of all its holdings. Sg Americas Secs Lc has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Ny State Common Retirement Fund reported 83,800 shares. Baker Bros Advisors Limited Partnership reported 11.72M shares. Da Davidson And stated it has 2,000 shares.

The stock of BioCryst Pharmaceuticals, Inc. (BCRX) formed a descending triangle with $4.75 target or 4.00 % above today’s $4.57 share price. The 7 months triangle pattern indicates low risk for the $449.71M company. If the $4.75 price target is reached, the company will be worth $17.99M more.
The descending triangle is in our view more reliable than the ascending one. The descending triangle pattern has break even failure rate for up and down breakouts of 7% and 16%, respectively. The average rise and decline is 47% and 16%. The throwback or so called pullback rates are: 37% and 54%. The stocks meeting their targets is high for this type of breakout: 84% and 54% percent.

The stock decreased 0.44% or $0.02 during the last trading session, reaching $4.57. About 663,349 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since December 8, 2016 and is uptrending. It has outperformed by 58.38% the S&P500.

Analysts await BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings on February, 26. They expect $-0.15 EPS, down 150.00 % or $0.09 from last year’s $-0.06 per share. After $-0.18 actual EPS reported by BioCryst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -16.67 % EPS growth.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Among 13 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. BioCryst Pharmaceuticals had 31 analyst reports since August 7, 2015 according to SRatingsIntel. Piperjaffray upgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Friday, August 12 to “Overweight” rating. JMP Securities maintained the shares of BCRX in report on Tuesday, November 28 with “Buy” rating. The firm earned “Buy” rating on Thursday, February 16 by Ladenburg Thalmann. On Friday, August 5 the stock rating was maintained by Jefferies with “Hold”. H.C. Wainwright maintained BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Friday, May 26 with “Buy” rating. JP Morgan downgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rating on Tuesday, February 9. JP Morgan has “Neutral” rating and $5 target. The rating was maintained by Noble Financial on Friday, May 26 with “Buy”. The firm has “Hold” rating by Jefferies given on Wednesday, September 9. As per Tuesday, August 8, the company rating was maintained by H.C. Wainwright. The company was upgraded on Wednesday, January 6 by Jefferies.

More news for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were recently published by:, which released: “Biotech Stock Performance Review — BioCryst Pharma, Celgene, Exelixis, and Geron” on November 21, 2017.‘s article titled: “BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q3 2017 Results …” and published on November 07, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.